If you have been reading about 反相色谱 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-09-20. Where a claim depends on a specific study, the study is described rather than over-claimed.
纯度评估通常综合反相色谱、体积排阻色谱与质谱三方面信息：前者反映疏水性杂质，后者反映聚集体，质谱则确认分子量与主要降解产物。有关降解途径的完整图谱——例如脱酰胺、氧化与水解各占多大比例——在不同储存条件下仍有差异，属于需要逐案验证的问题。
质量控制环节关注外观、含量、纯度、有关物质、水分与微生物限度等项目。检测结果需要有对照品和系统适用性数据支持，单次测定不足以判定批次的稳定性。实验室之间方法转移时，色谱柱品牌与梯度差异常导致保留时间漂移，因此方法验证十分必要。
Common degradation routes include hydrolysis of labile amide bonds, deamidation of asparagine and glutamine residues, oxidation of methionine and tryptophan, and non-covalent aggregation. Aggregates can form during freeze-thaw cycling, at elevated pH, or when peptide concentration is high. Each route produces characteristic chromatographic or mass shifts that are tracked during stability studies. Whether a given minor impurity alters biological activity is often an open question, and specification limits are typically set on identity and purity rather than on functional data for trace species.
Lyophilized material is generally held at -20 degrees Celsius or lower, desiccated and protected from light, where it remains stable for extended periods. Reconstituted or ready-to-use solution is usually kept at 2 to 8 degrees Celsius with minimal agitation. Repeated freeze-thaw cycles should be avoided because they promote aggregation and reduce the soluble monomer fraction. Shipment of frozen solid commonly uses dry ice, while refrigerated liquid moves with validated cold packs. Stability beyond documented periods is not established.
| Property | Value | Notes |
|---|---|---|
| 储存温度 | 2 至 8 摄氏度 | 固体粉末，避光密封 |
| 外观 | 白色至类白色冻干粉 | 溶解后为澄清至微乳光 |
| 溶解性 | 易溶于水性缓冲液 | 避免剧烈振荡 |
| 常规纯度方法 | 反相高效液相色谱 | 紫外或质谱检测 |
| 定量方法 | 液相色谱串联质谱 | 配合固相萃取前处理 |
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.
当前公开资料把 tirzepatide 归为肠促胰素类受体双重激动剂。它并非激素天然变体，而是经过序列改造的工程化肽。其分子量、等电点与疏水性等基础参数已在药典和化学数据库中收录，可作为分析检测和质量研究的参照。
Tirzepatide 是一种由 39 个氨基酸组成的合成肽，分子结构上以 GIP 序列为骨架并引入脂肪酸侧链修饰，使其能够同时与葡萄糖依赖性促胰岛素多肽（GIP）受体和胰高血糖素样肽-1（GLP-1）受体结合。这种双重激动特性使它在同类肽类药物中区别于选择性 GLP-1 受体激动剂。该分子最早由一家制药公司在 2010 年代报道，随后进入糖尿病与体重管理领域的临床研究。
在生理层面，GIP 与 GLP-1 均为肠道内分泌细胞分泌的肠促胰素，进食后参与胰岛素分泌调节与胃排空抑制。Tirzepatide 通过同时激活这两条信号通路，使胰岛素分泌的葡萄糖依赖性增强，并延缓冲胃排空、降低食欲信号。与单一 GLP-1 激动相比，双靶点作用在血糖控制和体重变化上的效应幅度更大，但具体贡献比例仍在研究之中。
Tirzepatide is a synthetic peptide of 39 amino acids engineered from the native glucose-dependent insulinotropic polypeptide sequence. Its structure incorporates several non-natural residues and a C-terminal segment derived from glucagon-like peptide-1, together with a C20 fatty diacid moiety attached through a linker. The lipophilic side chain promotes binding to serum albumin, which slows renal clearance after administration. The compound is classified as a dual incretin receptor agonist and is supplied as a lyophilized powder for reconstitution or as a preformulated solution, depending on the presentation.
The peptide activates two G protein-coupled receptors, GIPR and GLP-1R. Binding triggers adenylyl cyclase activity and raises intracellular cyclic AMP in pancreatic beta cells, which potentiates insulin release when glucose is elevated. Signaling in the central nervous system is associated with reduced appetite and lower energy intake, while effects on gastric emptying and glucagon secretion are also reported. Because activity at both receptors is retained, the pharmacological profile is often described as incretin-based rather than selective for a single receptor.
After subcutaneous injection, absorption is gradual, and peak plasma levels are generally reached within one to three days. Albumin binding extends the apparent half-life to roughly five days, which supports a weekly administration schedule. Metabolism proceeds mainly through proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid chain, rather than through cytochrome P450 pathways. Eliminated fragments are largely recycled through general protein turnover, and excretion of intact drug in urine is minimal. These properties distinguish the molecule from short-acting incretin mimetics.
Like most synthetic peptides of this size, the material is commonly supplied as a lyophilised powder that appears white to off-white. It dissolves in aqueous buffers and in mixtures of water with a small proportion of organic solvent, though the fatty acid portion reduces solubility in pure water relative to short peptides. Hygroscopic behaviour is reported for many peptide powders, so weighing is usually performed quickly and under controlled humidity. Working solutions are typically prepared fresh and kept cold.
Long-term storage of lyophilised peptide powder is generally at minus twenty degrees Celsius or colder, with desiccant and protection from light. Short-term storage at two to eight degrees Celsius is common during active use. In solution, stability depends strongly on pH, concentration, and the presence of preservatives, and hydrolysis or aggregation can develop over weeks. Published stability data specific to this molecule are limited, so recommended conditions for research material are usually extrapolated from general peptide handling practice rather than from a dedicated study.
Bulk peptide material is normally characterised by reversed-phase high-performance liquid chromatography, which separates the target sequence from truncation products and other closely related impurities. Ultraviolet detection near 214 nanometres is common because the peptide backbone absorbs in that region. Mass spectrometry, usually electrospray ionisation coupled to a mass analyser, is used to confirm the molecular mass. Because the molecule carries a lipophilic side chain, gradient methods often need a relatively high organic modifier fraction to elute it within a practical retention window.
=== D-dimer === A measurement of blood D-dimer level may be useful in diagnostic evaluation. A level less than 500 ng/ml may be considered evidence against a diagnosis of aortic dissection, although this guideline is only applicable in cases deemed "low risk" and within 24 hours of symptom onset. The American Heart Association does not advise using this test in making the diagnosis, as evidence is still tentative.
==== Comorbid personality disorders ==== Approximately 74% of individuals with BPD also fulfill criteria for another personality disorder during their lifetime, according to research published in 2008. The most prevalent co-occurring disorders are from Cluster A (paranoid, schizoid, and schizotypal personality disorders), affecting about half of those with BPD, with schizotypal personality disorder alone impacting one-third of individuals. Being part of Cluster B, BPD patients also commonly share characteristics with other Cluster B disorders (antisocial, histrionic, and narcissistic personality disorders), with nearly half of individuals with BPD showing signs of these conditions, and narcissistic personality disorder affecting roughly one-third. Cluster C disorders (avoidant, dependent, and obsessive-compulsive personality disorders) have the least comorbidity with BPD, with just under a third of individuals with BPD meeting the criteria for a Cluster C disorder.
== See also == Deputy (legislator) Member of Congress Australia and New Zealand Association of Clerks-at-the-Table, an association with the aim of advancing the professional development of parliamentarians.
==== Indigenous affairs ==== Upon taking office, Lula also issued the Provisional measure No. 1,154, of 1 January 2023, which created the Ministry of Indigenous People, and also renamed the Fundação Nacional do Índio ("National Indian Foundation, FUNAI") to Fundação Nacional dos Povos Indígenas ("National Indigenous People Foundation"), in addition to linking this foundation authority to the newly created ministry (it was previously linked to the Ministry of Agriculture). He appointed Sônia Guajajara as Indigenous minister, and Joenia Wapichana to head FUNAI, being the first indigenous women to head such offices. On 3 January 2023, Joenia Wapichana announced the creation of several working groups to resume the demarcation of indigenous lands that had been paralyzed in the previous years (such as the Jeju and Areal Indigenous Lands in Pará, Tekoha Porã, Karugwá and Pyhaú lands in São Paulo, Ka'aguy Poty in Rio Grande do Sul, Cambirela in Santa Catarina, Passo Piraju/Nu Porã in Mato Grosso do Sul and the area claimed by the Mukurin people in Minas Gerais), in addition to establishing new groups (for the Aranã and Aranã Caboclo Índio indigenous lands in Minas Gerais and the areas claimed by the Cassupá and Salamãi ethnic groups in Rondônia).
Sources: en.wikipedia.org
Regular production batches of 238PuO2 particles precipitated as a hydroxide were used to show that large production batches could be effectively 16O2-exchanged on a routine basis. High-fired 238PuO2 microspheres were successfully 16O2-exchanged showing that an exchange will take place regardless of the previous heat treatment history of the 238PuO2. This lowering of the neutron emission rate of PuO2 containing normal oxygen by a factor of five was discovered during the cardiac pacemaker research at Mound Laboratory in 1966, due in part to the Mound Laboratory's experience with production of stable isotopes beginning in 1960. For production of the large heat sources the shielding required would have been prohibitive without this process. Unlike the other three isotopes discussed in this section, 238Pu must be specifically synthesized and is not abundant as a nuclear waste product. At present only Russia has maintained high-volume production, while in the US, no more than 50 g (1.8 oz) were produced in total between 2013 and 2018. The US agencies involved desire to begin the production of the material at a rate of 300 to 400 grams (11 to 14 oz) per year. If this plan is funded, the goal would be to set up automation and scale-up processes in order to produce an average of 1.5 kg (3.3 lb) per year by 2025.
Urocortin III, a 38–41 amino acid peptide, is a member of the CRF (corticotropin-releasing factor), also known as CRH (corticotropin-releasing hormone) family of peptides, with a long evolutionary lineage. Separate chromosomes harbouring two exons each are home to the genes encoding UCN, UCN2, and UCN3. A gene on human chromosome 10p15 at location 5.40 Mb encodes the urocortin, UCN III, which has been discovered more recently. A 161 amino acid precursor is produced when the UCN III gene is translated. Mature UCN III with 38 or 41 amino acids would be produced by proteolytic cleavage between arginine- or threonine-lysine residues. Human plasma contains both the 38 and 41 amino acid forms of UCN III, although the 38 amino acid form is more prevalent, according to findings from high-performance liquid chromatography. Each urocortin peptide has a distinct expression location and function, yet they all share conserved structural similarity. Urocortins' structures, as determined by nuclear magnetic resonance, exhibit alpha-helical secondary structures, which support biological activity and binding selectivity.
(2026) report evidence from the study of carbon and oxygen stable isotope compositions of mammal fossils from the Pinturas Formation (Argentina) indicative of presence of a diverse range of habitats in Patagonia during the Miocene, and interpret the diversity of the primate assemblage from the studied formation as likely linked to habitat diversity. Cooke et al. (2026) report the first discovery of mandibular remains of Stirtonia victoriae from the La Victoria Formation (Colombia), and interpret their anatomy as indicative of leaf-eating adaptations of the studied monkey. Urciuoli et al. (2026) determine the phylogenetic relationships of early members of Catarrhini on the basis of the study of the semicircular canal and vestibule shape in Saadanius, Pliobates, Ekembo and Victoriapithecus, interpret Saadanius as most likely to be a stem catarrhine that evolved ossified tubular ectotympanic independently from crown catarrhines, and interpret pliopithecoids as most likely to be stem catarrhines closer to the crown group than Saadanius. Arias-Martorell et al. (2026) report evidence of similarities of shape of the radial head of Pliobates cataloniae and extant apes, and interpret Pliobates as better adapted to climbing than to behaviors involving forelimb-dominated suspension. Arias-Martorell et al. (2026) compare the shape of the distal part of the humerus of Pliobates cataloniae and other extinct and extant simians, and interpret Pliobates as unlikely to perform acrobatic suspensory behaviors seen in extant gibbons.
Sources: en.wikipedia.org
AM function can be compared to another peptide called pro-adrenomedullin N-terminal 20 peptide (PAMP), which both originate from a common precursor leading to angiogenesis, vasodilation, and anti-inflammatory processes. These two peptides are expressed in the gastrointestinal (GI) tract at a mass level, serving as GI hormones controlling processes like insulin secretion and gastric emptying. Past studies reveal that AM and PAMP also impact gut microbiome composition by fostering the development of beneficial bacteria (i.e., Bifidobacterium and Lactobacillus) and diminishing detrimental microbes.
Because of its central role in controlling eukaryotic gene expression, P-TEFb is subject to stringent regulation at the level of transcription of the genes encoding the subunits, translation of the subunit mRNAs, turnover of the subunits, and also by an unusual mechanism involving the 7SK snRNP. As shown in Figure 3 P-TEFb is held in the 7SK snRNP by the double stranded RNA binding protein HEXIM (HEXIM1 or HEXIM2 in humans). HEXIM bound to 7SK RNA or any double stranded RNA binds to P-TEFb and inhibits the kinase activity. Two other proteins are always found associated with 7SK RNA. The methyl phosphase capping enzyme MEPCE puts a methyl group on the gamma phosphate of the first nucleotide of the 7SK RNA and the La related protein LARP7 binds to the 3' end of 7SK. When P-TEFb is extracted from the 7SK snRNP, 7SK RNA undergoes a conformation change, HEXIM is ejected and hnRNPs take the place of the factors removed. The re-sequestration of P-TEFb requires another rearrangement of the RNA, binding of HEXIM and then P-TEFb. In rapidly growing cells the 7SK snRNP is the predominant form of P-TEFb. For review.
== They Hunger: Lost Souls == A commercial sequel, They Hunger: Lost Souls, was announced on October 20, 2005. It was developed on the Source engine and was 75% complete at the time of the announcement. The game was set in North-Eastern Europe during the early 1960's. The development of the game stopped after 2008. Two playable alpha builds were leaked in 2019.
==== Addictiveness and dependence ==== Frequent use of GHB or GBL, even when taken long-term and in moderate doses, does not appear to cause significant physical dependency in the majority of its users. In many people, quitting or temporarily abstaining from use of the drugs is achieved with minimal or no difficulty. However, when consumed in excessive amounts with a high frequency of dosing, physical and psychological dependence can develop. Management of GBL dependence involves considering the person's age, comorbidity and the pharmacological pathways of GBL. GHB and GBL users can adopt a '24/7' dosing regime. This is where the user has become tolerant to the effects of the drug, increasing the dosage and frequency of dosage simply to avoid withdrawal symptoms. For those users who do report withdrawal symptoms upon quitting the use of GHB or GBL, symptoms seem to depend on the dosage and the length of time the drug was used. Light to moderate users often experience insomnia and sleep-related problems, whereas heavy, prolonged use can cause severe withdrawal symptoms similar to Benzodiazepine withdrawal syndrome (BWS).
Sources: en.wikipedia.org
建议在低温、避光、干燥环境中密封保存，常见条件为 2 至 8 摄氏度，长期存放可置于更低温度。应避免反复冻融，并尽量减少容器开启次数。
溶解后的稳定时间通常短于固体形态，受浓度、缓冲液和容器材质影响。冷藏条件下一般只能维持较短时间，具体期限应通过实际稳定性实验确认。
反相高效液相色谱用于纯度与含量测定，液相色谱串联质谱用于生物基质中的定量，体积排阻色谱用于检测聚集体。多种方法结合才能较完整地表征样品。
Reversed-phase high-performance liquid chromatography is the standard approach, separating the main peak from related impurities. Ultraviolet detection near 214 nanometers captures the peptide backbone. Mass spectrometry is then used alongside chromatography to confirm identity and detect covalent modifications.